What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Autoimmune Disease Orphan Drug

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307752

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307752

NA Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

PUBLISHED: June 1, 2023

PAGES: 165 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The North America pemphigus vulgaris market is expected to reach USD 313.87 million by 2030 from USD 165.49 million in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.

Market Segmentation:

North America Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of North America Pemphigus Vulgaris Market Dynamics :

Driver
Rise in patients with rare diseases such as pemphigus vulgaris
Restraint
High cost of treatment
Opportunity
Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the Market are:

F-Hoffmann La Roche Ltd.
Sanofi
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Celltrion Healthcare Co., Ltd.
AbbVie Inc.
Novartis AG
Amgen Inc.
Merck & Co., Inc.
AstraZeneca
Teva Pharmaceutical Industries Ltd
Lilly
Zydus Group
GSK plc.

1 INTRODUCTION 31

1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33

2 MARKET SEGMENTATION 36

2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.6 MULTIVARIATE MODELLING 43
2.7 MARKET APPLICATION COVERAGE GRID 44
2.8 PRODUCT LIFELINE CURVE 45
2.9 DBMR MARKET POSITION GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PESTEL ANALYSIS 52
4.2 PORTER FIVE FORCES 53
4.3 PATENT ANALYSIS 54
4.4 PATIENT FLOW DIAGRAM 55
4.5 KEY PRICING STRATEGIES 56
4.6 FUTURE THERAPIES 57
4.7 KEY PATIENT ENROLLMENT STRATEGIES 58

5 PIPELINE ANALYSIS 59

6 EPIDEMIOLOGY 60

7 INDUSTRY INSIGHTS 61

8 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: REGULATIONS 62

9 MARKET OVERVIEW 65

9.1 DRIVERS 67
- 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
- 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
- 9.1.3 AWARENESS REGARDING THE DISEASE 68
9.2 RESTRAINTS 68
- 9.2.1 STRICT REGULATORY GUIDELINES 68
- 9.2.2 HIGH TREATMENT COSTS 68
9.3 OPPORTUNITIES 69
- 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
- 9.3.2 INCREASING HEALTHCARE FACILITIES 69
- 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
9.4 CHALLENGES 70
- 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
- 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71

10 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72

10.1 OVERVIEW 73
10.2 TREATMENT 76
- 10.2.1 MEDICATIONS, BY TYPE 76
  - 10.2.1.1 CORTICOSTEROIDS 77
  - 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
    - 10.2.1.2.1 AZATHIOPRINE 78
    - 10.2.1.2.2 MYCOPHENALATE MOFETIL 78
    - 10.2.1.2.3 METHOTREXATE 78
    - 10.2.1.2.4 CYCLOPHOSPHAMIDE 78
    - 10.2.1.2.5 MIZORIBINE 78
    - 10.2.1.2.6 OTHERS 78
  - 10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
    - 10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
    - 10.2.1.3.2 TETRACYCLINE 79
    - 10.2.1.3.3 OTHERS 79
  - 10.2.1.4 BIOLOGICS 79
  - 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
  - 10.2.1.6 ANTIBIOTICS 79
  - 10.2.1.7 ANTIFUNGALS 79
  - 10.2.1.8 ANTIVIRALS 79
  - 10.2.1.9 OTHER MEDICATIONS 79
- 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
  - 10.2.2.1 ORAL 80
  - 10.2.2.2 TOPICAL 80
  - 10.2.2.3 PARENTERAL 80
  - 10.2.2.4 OTHERS 80
- 10.2.3 MEDICATIONS, BY DRUG TYPE 80
  - 10.2.3.1 GENERIC 81
  - 10.2.3.2 BRANDED 81
10.3 DIAGNOSIS 81
- 10.3.1 SKIN BIOPSY 82
- 10.3.2 BLOOD TEST 82
- 10.3.3 ENDOSCOPY 82

11 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83

11.1 OVERVIEW 84
11.2 ADULTS 87
11.3 GERIATRIC 88
11.4 PEDIATRIC 89

12 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER 90

12.1 OVERVIEW 91
12.2 HOSPITALS 94
12.3 SPECIALTY CLINICS 94
12.4 RESEARCH INSTITUTES 95
12.5 OTHERS 96

13 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97

13.1 OVERVIEW 98
13.2 HOSPITALS PHARMACY 101
13.3 RETAIL PHARMACY 101
13.4 ONLINE PHARMACY 102

14 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY REGION 103

14.1 NORTH AMERICA 104
- 14.1.1 U.S. 112
- 14.1.2 CANADA 116
- 14.1.3 MEXICO 120

15 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 124

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 124

16 SWOT ANALYSIS 125

17 COMPANY PROFILE 126

17.1 ABBVIE INC. 126
- 17.1.1 COMPANY SNAPSHOT 126
- 17.1.2 REVENUE ANALYSIS 126
- 17.1.3 COMPANY SHARE ANALYSIS 127
- 17.1.4 PRODUCT PORTFOLIO 127
- 17.1.5 RECENT DEVELOPMENTS 128
17.2 MERCK & CO., INC., 129
- 17.2.1 COMPANY SNAPSHOT 129
- 17.2.2 REVENUE ANALYSIS 129
- 17.2.3 COMPANY SHARE ANALYSIS 130
- 17.2.4 PRODUCT PORTFOLIO 130
- 17.2.5 RECENT DEVELOPMENT 130
17.3 SANOFI 131
- 17.3.1 COMPANY SNAPSHOT 131
- 17.3.2 REVENUE ANALYSIS 131
- 17.3.3 COMPANY SHARE ANALYSIS 132
- 17.3.4 PRODUCT PORTFOLIO 132
- 17.3.5 RECENT DEVELOPMENT 132
17.4 REGENERON PHARMACEUTICALS INC. 133
- 17.4.1 COMPANY SNAPSHOT 133
- 17.4.2 REVENUE ANALYSIS 133
- 17.4.3 COMPANY SHARE ANALYSIS 134
- 17.4.4 PRODUCT PORTFOLIO 134
- 17.4.5 RECENT DEVELOPMENT 134
17.5 NOVARTIS AG 135
- 17.5.1 COMPANY SNAPSHOT 135
- 17.5.2 REVENUE ANALYSIS 135
- 17.5.3 COMPANY SHARE ANALYSIS 136
- 17.5.4 PRODUCT PORTFOLIO 136
- 17.5.5 RECENT DEVELOPMENT 136
17.6 AMGEN INC. 137
- 17.6.1 COMPANY SNAPSHOT 137
- 17.6.2 REVENUE ANALYSIS 137
- 17.6.3 PRODUCT PORTFOLIO 138
- 17.6.4 RECENT DEVELOPMENTS 138
17.7 ASTRAZENECA 139
- 17.7.1 COMPANY SNAPSHOT 139
- 17.7.2 REVENUE ANALYSIS 139
- 17.7.3 COMPANY SHARE ANALYSIS 140
- 17.7.4 PRODUCT PORTFOLIO 140
- 17.7.5 RECENT DEVELOPMENTS 141
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 142
- 17.8.1 COMPANY SNAPSHOT 142
- 17.8.2 REVENUE ANALYSIS 142
- 17.8.3 PRODUCT PORTFOLIO 143
- 17.8.4 RECENT DEVELOPMENT 143
17.9 CELLTRION HEALTHCARE CO., LTD 144
- 17.9.1 COMPANY SNAPSHOT 144
- 17.9.2 REVENUE ANALYSIS 144
- 17.9.3 PRODUCT PORTFOLIO 145
- 17.9.4 RECENT DEVELOPMENTS 145
17.10 F. HOFFMANN- LA ROCHE LTD. 146
- 17.10.1 COMPANY SNAPSHOT 146
- 17.10.2 REVENUE ANALYSIS 146
- 17.10.3 PRODUCT PORTFOLIO 147
- 17.10.4 RECENT DEVELOPMENT 147
17.11 FRESENIUS KABI AG 148
- 17.11.1 COMPANY SNAPSHOT 148
- 17.11.2 REVENUE ANALYSIS 148
- 17.11.3 PRODUCT PORTFOLIO 149
- 17.11.4 RECENT DEVELOPMENT 149
17.12 GSK PLC 150
- 17.12.1 COMPANY SNAPSHOT 150
- 17.12.2 REVENUE ANALYSIS 150
- 17.12.3 PRODUCT PORTFOLIO 151
- 17.12.4 RECENT DEVELOPMENT 151
17.13 JOHNSON & JOHNSON SERVICES, INC. 152
- 17.13.1 COMPANY SNAPSHOT 152
- 17.13.2 REVENUE ANALYSIS 152
- 17.13.3 COMPANY SHARE ANALYSIS 153
- 17.13.4 PRODUCT PORTFOLIO 153
- 17.13.5 RECENT DEVELOPMENT 153
17.14 LILLY 154
- 17.14.1 COMPANY SNAPSHOT 154
- 17.14.2 REVENUE ANALYSIS 154
- 17.14.3 PRODUCT PORTFOLIO 155
- 17.14.4 RECENT DEVELOPMENT 155
17.15 PFIZER INC. 156
- 17.15.1 COMPANY SNAPSHOT 156
- 17.15.2 REVENUE ANALYSIS 156
- 17.15.3 PRODUCT PORTFOLIO 157
- 17.15.4 RECENT DEVELOPMENT 157
17.16 RAKSHIT DRUGS PVT. LTD 158
- 17.16.1 COMPANY SNAPSHOT 158
- 17.16.2 PRODUCT PORTFOLIO 158
- 17.16.3 RECENT DEVELOPMENT 158
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 159
- 17.17.1 COMPANY SNAPSHOT 159
- 17.17.2 REVENUE ANALYSIS 159
- 17.17.3 PRODUCT PORTFOLIO 160
- 17.17.4 RECENT DEVELOPMENT 160
17.18 ZYDUS GROUP 161
- 17.18.1 COMPANY SNAPSHOT 161
- 17.18.2 REVENUE ANALYSIS 161
- 17.18.3 PRODUCT PORTFOLIO 162
- 17.18.4 RECENT DEVELOPMENT 162

18 QUESTIONNAIRE 163

19 RELATED REPORTS 165

LIST OF TABLES

TABLE 1 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 39
TABLE 2 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 44
TABLE 3 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 60
TABLE 4 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 5 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 62
TABLE 6 NORTH AMERICA STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 62
TABLE 7 NORTH AMERICA ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 63
TABLE 8 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 65
TABLE 9 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 65
TABLE 10 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 11 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 67
TABLE 12 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 71
TABLE 13 NORTH AMERICA ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 14 NORTH AMERICA GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 15 NORTH AMERICA PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 16 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 78
TABLE 17 NORTH AMERICA HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 18 NORTH AMERICA SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 19 NORTH AMERICA RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 20 NORTH AMERICA OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 21 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 85
TABLE 22 NORTH AMERICA HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 23 NORTH AMERICA RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 24 NORTH AMERICA ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 25 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 93
TABLE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 93
TABLE 27 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
TABLE 28 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 94
TABLE 29 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 94
TABLE 30 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 94
TABLE 31 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 95
TABLE 32 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 95
TABLE 33 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 95
TABLE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 96
TABLE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 96
TABLE 36 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 97
TABLE 37 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
TABLE 38 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
TABLE 39 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
TABLE 40 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 98
TABLE 41 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 99
TABLE 42 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
TABLE 43 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 99
TABLE 44 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 99
TABLE 45 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 100
TABLE 46 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 101
TABLE 47 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
TABLE 48 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
TABLE 49 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
TABLE 50 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 102
TABLE 51 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 103
TABLE 52 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
TABLE 53 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 103
TABLE 54 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 55 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 104
TABLE 56 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 105
TABLE 57 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 58 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 59 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 60 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 106
TABLE 61 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 107
TABLE 62 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
TABLE 63 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 107
TABLE 64 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 107
TABLE 65 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108

LIST OF FIGURES

FIGURE 1 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SEGMENTATION 20
FIGURE 2 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 23
FIGURE 3 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 24
FIGURE 4 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 28
FIGURE 8 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 30
FIGURE 9 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 31
FIGURE 10 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SEGMENTATION 34
FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 35
FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 35
FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 39
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA PEMPHIGUS VULGARIS MARKET 50
FIGURE 15 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 57
FIGURE 16 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 58
FIGURE 17 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 58
FIGURE 18 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 59
FIGURE 19 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 68
FIGURE 20 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 69
FIGURE 21 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 69
FIGURE 22 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 70
FIGURE 23 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 75
FIGURE 24 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 76
FIGURE 25 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 76
FIGURE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 77
FIGURE 27 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 82
FIGURE 28 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 83
FIGURE 29 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 83
FIGURE 30 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 84
FIGURE 31 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 89
FIGURE 32 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 90
FIGURE 33 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 90
FIGURE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 91
FIGURE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023-2030) 91
FIGURE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 108

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ